486 related articles for article (PubMed ID: 24727984)
1. Successes and limitations of targeted cancer therapy in breast cancer.
Curigliano G; Criscitiello C
Prog Tumor Res; 2014; 41():15-35. PubMed ID: 24727984
[TBL] [Abstract][Full Text] [Related]
2. New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance.
Curigliano G
Cancer Treat Rev; 2012 Jun; 38(4):303-10. PubMed ID: 21764517
[TBL] [Abstract][Full Text] [Related]
3. Overcoming implementation challenges of personalized cancer therapy.
Meric-Bernstam F; Mills GB
Nat Rev Clin Oncol; 2012 Sep; 9(9):542-8. PubMed ID: 22850751
[TBL] [Abstract][Full Text] [Related]
4. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
5. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
6. Successes and limitations of targeted cancer therapy in melanoma.
Romano E; Michielin O
Prog Tumor Res; 2014; 41():78-88. PubMed ID: 24727988
[TBL] [Abstract][Full Text] [Related]
7. Clinical Diagnosis and Management of Breast Cancer.
McDonald ES; Clark AS; Tchou J; Zhang P; Freedman GM
J Nucl Med; 2016 Feb; 57 Suppl 1():9S-16S. PubMed ID: 26834110
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
9. Precision cancer medicine: where to target?
Yu Q; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154
[No Abstract] [Full Text] [Related]
10. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract][Full Text] [Related]
11. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
[TBL] [Abstract][Full Text] [Related]
12. The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?
Andre F; Vicier C; Delaloge S
Am Soc Clin Oncol Educ Book; 2014; ():e5-10. PubMed ID: 24857146
[TBL] [Abstract][Full Text] [Related]
13. Is precision medicine ready for use in breast cancer?
Pusztai L
Clin Adv Hematol Oncol; 2016 Dec; 14(12):964-966. PubMed ID: 28212357
[No Abstract] [Full Text] [Related]
14. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
[TBL] [Abstract][Full Text] [Related]
15. Personalised cancer medicine.
Jackson SE; Chester JD
Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.
Lang JE; Wecsler JS; Press MF; Tripathy D
J Surg Oncol; 2015 Jan; 111(1):81-90. PubMed ID: 25091830
[TBL] [Abstract][Full Text] [Related]
17. Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.
Fang J; Cai C; Wang Q; Lin P; Zhao Z; Cheng F
CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):177-187. PubMed ID: 28294568
[TBL] [Abstract][Full Text] [Related]
18. [BREAST CANCER: FROM TARGETED THERAPY TO PRECISION MEDICINE].
Jerusalem G; Collignon J; Josse C; Schroeder H; Rorive A; Frères P; Lambert F; Koopmansch B; Poncin A; Bours V
Rev Med Liege; 2015; 70(5-6):269-76. PubMed ID: 26285451
[TBL] [Abstract][Full Text] [Related]
19. Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.
Merajver S; Phadke S; Soellner M
Trans Am Clin Climatol Assoc; 2017; 128():169-179. PubMed ID: 28790501
[TBL] [Abstract][Full Text] [Related]
20. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
Tsimberidou AM; Ringborg U; Schilsky RL
Am Soc Clin Oncol Educ Book; 2013; ():118-25. PubMed ID: 23714475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
